Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Essex Bio-Technology ( (HK:1061) ) has provided an announcement.
Essex Bio-Technology Limited has announced the completion of the last patient last visit in an international multi-centre phase 3 clinical study for HLX04-O, a bio-pharmaceutical product for treating wet-AMD. This study compares the efficacy and safety of HLX04-O with ranibizumab, aiming to fill a gap in the Chinese market where no bevacizumab product for wet-AMD is currently approved.
More about Essex Bio-Technology
Essex Bio-Technology Limited is a biopharmaceutical company focused on developing innovative treatments, particularly in the field of ophthalmology. The company co-develops bio-pharmaceutical products such as anti-VEGF drugs for treating conditions like exudative (wet) age-related macular degeneration, collaborating with partners like Shanghai Henlius Biotech, Inc.
YTD Price Performance: -2.72%
Average Trading Volume: 270,616
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.62B
For an in-depth examination of 1061 stock, go to TipRanks’ Stock Analysis page.